Friday, March 31, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

Bavarian Nordic Provides 2016 Update

by Global Biodefense Staff
November 12, 2016
Biodefense and Vaccine Industry News

Bavarian Nordic, a biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases, this week announced interim financial results for the first three quarters of 2016.

The company has developed a portfolio of vaccines for infectious diseases, including the non-replicating smallpox vaccine, IMVAMUNE®, which is stockpiled for emergency use by the U.S. and approved in the European Union (under the trade name IMVANEX®) and in Canada. Bavarian Nordic and its partner Janssen are developing an Ebola vaccine regimen, which has been fast-tracked, with the backing of worldwide health authorities, and a vaccine for the prevention and treatment of HPV.

Key highlights from 2016 include:

  • In September, Janssen completed a submission for Emergency Use Assessment and Listing for the Ad26.ZEBOV/MVA-BN Filo prime-boost Ebola vaccine regimen to the World Health Organization
  • In October, the first Phase 2 clinical trial of Respiratory Syncytial Virus (RSV) Vaccine Candidate MVA-BN RSV was initiated. The study will help to identify the optimal dose and schedule for a subsequent Phase 2b field efficacy study planned for initiation in 2017
  • In September, Phase 1 results for the MVA-BN RSV vaccine were presented at the 10th International Respiratory Syncytial Virus Symposium
  • In September, Christopher Heery, M.D. was appointed Chief Medical Officer of Bavarian Nordic with immediate effect
  • In August, Bavarian Nordic entered a drug supply agreement with Bristol-Myers Squibb, providing OPDIVO for the upcoming clinical trial of cancer immunotherapy candidate CV301 in non-small cell lung cancer.

Revenue for the nine-month period ending September 30, 2016 was DKK 591 million, of which DKK 452 million was recognized in the third quarter. This is in line with the Company’s expectations, as the majority of revenue relates to production of IMVAMUNE bulk drug substance produced for the U.S. Government, which primarily occurs in the second half of 2016. Thus approximately 40% of the year’s revenue is expected to be recognized in the last quarter of 2016.

Tags: EbolaPoxvirusesSmallpox

Related Posts

Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC